Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...

Novo Nordisk ... GLP-1 products, according to the company's earnings report Wednesday. Of that, Wegovy grew by 150% compared to 2023. Anjalee Khemlani is the senior health reporter at Yahoo ...

Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

Novo Nordisk has proven once again that it is the world leader in the vast diabetes and weight-loss drug market. Demand for its products is ... the population's poor health habits.

Novo Nordisk has been manufacturing some active pharmaceutical ingredients, and finished products ... administration’s ambition of improving health and managing chronic diseases,” he told ...

The European Commission has granted marketing authorisation for Novo Nordisk’s adult diabetes ... Both of these products will be available in Europe in the Danish pharmaceutical company ...

The ad violates federal rules requiring “that advertising for prescription drugs – including compounded drugs – not be false ...

A new study examines how cost, side effects and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...